Genetic Testing for Inherited Thrombophilia

Policy # 00333
Original Effective Date: 12/19/2012
Current Effective Date: 01/09/2023

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers genetic testing for inherited thrombophilia, including testing for factor V Leiden (FVL) variant, prothrombin gene variants, and variants in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene to be investigational.*

Policy Guidelines

Genetics Nomenclature Update
The Human Genome Variation Society nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It is being implemented for genetic testing medical evidence review updates starting in 2017 (see Table PG1). The Society’s nomenclature is recommended by the Human Variome Project, the Human Genome Organization, and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology - “pathogenic,” “likely pathogenic,” “uncertain significance,” “likely benign,” and “benign” - to describe variants identified that cause Mendelian disorders.
Table PG1. Nomenclature to Report on Variants Found in DNA

<table>
<thead>
<tr>
<th>Previous Mutation</th>
<th>Updated Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutation</td>
<td>Disease-associated variant</td>
</tr>
<tr>
<td>Variant</td>
<td>Change in the DNA sequence</td>
</tr>
<tr>
<td>Familial variant</td>
<td>Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives</td>
</tr>
</tbody>
</table>

Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification

<table>
<thead>
<tr>
<th>Variant Classification</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathogenic</td>
<td>Disease-causing change in the DNA sequence</td>
</tr>
<tr>
<td>Likely pathogenic</td>
<td>Likely disease-causing change in the DNA sequence</td>
</tr>
<tr>
<td>Variant of uncertain significance</td>
<td>Change in DNA sequence with uncertain effects on disease</td>
</tr>
<tr>
<td>Likely benign</td>
<td>Likely benign change in the DNA sequence</td>
</tr>
<tr>
<td>Benign</td>
<td>Benign change in the DNA sequence</td>
</tr>
</tbody>
</table>

ACMG: American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

Genetic Counseling

Genetic counseling is primarily aimed at patients who are at risk for inherited disorders, and experts recommend formal genetic counseling in most cases when genetic testing for an inherited condition is considered. The interpretation of the results of genetic tests and the understanding of risk factors can be very difficult and complex. Therefore, genetic counseling will assist individuals in understanding the possible benefits and harms of genetic testing, including the possible impact of the information on the individual's family. Genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing. Genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.
Background/Overview
Venous Thromboembolism
The overall U.S. incidence of venous thromboembolism (VTE) is approximately 1 per 1,000 person-years, and the lifetime clinical prevalence is approximately 5%, accounting for 100,000 deaths annually. The risk is strongly age-related, with the greatest risk in older populations. Venous thromboembolism also recurs frequently; the estimated cumulative incidence of first VTE recurrence is 30% at 10 years. These figures do not separate patients with known predisposing conditions from those without.

Risk factors for thrombosis include clinical and demographic variables, and at least 1 risk factor can be identified in approximately 80% of patients with thrombosis. The following list includes the most important risk factors:

- Malignancy
- Immobility
- Surgery
- Obesity
- Pregnancy
- Hormonal therapy such as estrogen/progestin or selective estrogen modulator products
- Systemic lupus erythematosus and/or other rheumatologic disorders
- Myeloproliferative disorders
- Liver dysfunction
- Nephrotic syndrome
- Hereditary factors.

Pregnancy often is considered a special circumstance because of its frequency and unique considerations for preventing and treating VTE. Pregnancy is associated with a 5- to 10-fold increase in VTE risk, and absolute VTE risk in pregnancy is estimated to be 1 to 2 per 1000 deliveries. In women with a history of pregnancy-related VTE, risk of recurrent VTE with subsequent pregnancies is increased greatly at approximately 100-fold.

Treatment
Treatment of thrombosis involves anticoagulation for a minimum of 3 to 6 months. After this initial treatment period, patients deemed to be at a continued high risk for recurrent thrombosis may
continue on anticoagulation therapy for longer periods, sometimes indefinitely. Anticoagulation is effective for reducing the subsequent risk of thrombosis but carries its own risk of bleeding.

**Inherited Thrombophilia**

Inherited thrombophilias are a group of clinical conditions characterized by genetic variant defects associated with a change in the amount or function of a protein in the coagulation system and a predisposition to thrombosis. Not all individuals with a genetic predisposition to thrombosis will develop VTE. The presence of inherited thrombophilia will presumably interact with other VTE risk factors to determine an individual’s VTE risk.

A number of conditions fall under the classification of inherited thrombophilias. Inherited thrombophilias include the following conditions, which are defined by defects in the coagulation cascade:

- Activated protein C resistance (factor V Leiden [FVL] variant)
- Prothrombin (*factor II*) gene variant (G20210A)
- Protein C deficiency
- Protein S deficiency
- Prothrombin deficiency
- Hyper-homocysteinemia (5,10-methylenetetrahydrofolate reductase [*MTHFR*] variant).

The most common type of inherited thrombophilia is FVL, which accounts for up to 50% of inherited thrombophilia syndromes. Generally, routine testing for hypercoagulable disorders is not recommended in unselected patients. For those considered at risk (e.g., strong family history, recurrent thromboses), the prevalence of identifying an inherited thrombophilia ranges from 5% to 40%; the prevalence is estimated at 12% to 40% for FVL and 6% to 18% for prothrombin G20210A variant in this population.

**Genetic Testing**

Genetic testing for gene variants associated with thrombophilias is available for FVL, the prothrombin G20210A variant, and *MTHFR*. Genetic testing for inherited thrombophilia can be considered in several clinical situations. Clinical situations addressed herein include the following:

- Assessment of thrombosis risk in asymptomatic patients (screening for inherited thrombophilia)
Genetic Testing for Inherited Thrombophilia

Policy # 00333
Original Effective Date: 12/19/2012
Current Effective Date: 01/09/2023

- Evaluation of a patient with established thrombosis, for consideration of a change in anticoagulant management based on results
- Evaluation of close relatives of patients with documented inherited thrombophilia or with a clinical and family history consistent with an inherited thrombophilia
- Evaluation of patients in other situations who are considered at high-risk for thrombosis (eg, pregnancy, planned major surgery, exogenous hormone use).

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)
Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Commercial thrombophilia genetic tests are available under the auspices of the CLIA. Laboratories that offer laboratory-developed tests must be licensed by the CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration (FDA) has chosen not to require any regulatory review of this test.

The FDA has cleared several genetic tests for thrombophilia for marketing through the 510(k) process for use as an aid in the diagnosis of patients with suspected thrombophilia. Some of these tests are listed in Table 1.

Table 1. Genetic Tests for Thrombophilia Cleared by FDA

<table>
<thead>
<tr>
<th>Test</th>
<th>Manufacturer</th>
<th>Cleared</th>
<th>510(k) No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>cobas® Factor II and Factor V Test</td>
<td>Roche Molecular Systems, Inc.</td>
<td>01/12/18</td>
<td>K172913</td>
</tr>
<tr>
<td>IMPACT Dx™ Factor V Leiden and Factor II Genotyping Test</td>
<td>Agena Bioscience&lt;sup&gt;a&lt;/sup&gt;</td>
<td>06/14</td>
<td>K132978</td>
</tr>
<tr>
<td>Invader® Factor II, V, and MTHFR (677, 1298) tests</td>
<td>Hologic</td>
<td>04/06/11</td>
<td>K100943, K100980, K100987, K100496</td>
</tr>
</tbody>
</table>

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Genetic Testing for Inherited Thrombophilia

Policy # 00333
Original Effective Date: 12/19/2012
Current Effective Date: 01/09/2023

<table>
<thead>
<tr>
<th>Test Description</th>
<th>Manufacturer</th>
<th>Date</th>
<th>FDA Approval Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>VeraCode Genotyping Test for Factor V and Factor II</td>
<td>Illumina</td>
<td>04/28/10</td>
<td>K093129</td>
</tr>
<tr>
<td>eSensor Thrombophilia Risk Test, FII-FV, FII, FV and MTHFR (677, 1298) Genotyping Tests</td>
<td>GenMark Dx</td>
<td>04/22/10</td>
<td>K093974</td>
</tr>
<tr>
<td>INFINITI System Assay for Factor II &amp; Factor V</td>
<td>AutoGenomics</td>
<td>02/07/07</td>
<td>K060564</td>
</tr>
<tr>
<td>Xpert Factor II and Factor V Genotyping Assay</td>
<td>Cepheid</td>
<td>09/18/09</td>
<td>K082118</td>
</tr>
<tr>
<td>Verigene Factor F2, F5, and MTHFR Nucleic Acid Test</td>
<td>Nanosphere</td>
<td>10/11/07</td>
<td>K070597</td>
</tr>
<tr>
<td>Factor V Leiden Kit</td>
<td>Roche Diagnostics</td>
<td>12/17/03</td>
<td>K033607</td>
</tr>
<tr>
<td>Factor II (Prothrombin) G20210A Kit</td>
<td>Roche Diagnostics</td>
<td>12/20/03</td>
<td>K033612</td>
</tr>
</tbody>
</table>

Other commercial laboratories may offer a variety of functional assays and genotyping tests for F2 (prothrombin, coagulation factor II) and F5 (coagulation factor V), and single or combined genotyping tests for MTHFR.

FDA: Food and Drug Administration.

a FDA marketing clearance was granted to Sequenom Bioscience before it was acquired by Agena Bioscience.

b FDA marketing clearance was granted to Osmetech Molecular Diagnostics.
In November 2017, the 23andMe Personal Genome Service (PGS) Genetic Health Risk was granted a de novo classification by the FDA (class II with general and special controls, FDA product code: PTA). This is a direct-to-consumer test that has been evaluated by the FDA for accuracy, reliability, and consumer comprehension. This test reports whether an individual has variants associated with a higher risk of developing harmful blood clots. This report is based on a qualitative genetic test for single nucleotide polymorphism detection of Factor V Leiden variant in the $F_5$ gene (rs6025) and Prothrombin G20210A variant in the $F_2$ gene (rs1799963/i3002432). Similarly, in August 2020, Ancestry Genomics, Inc was granted the same de novo classification by the FDA (class II with general and special controls, FDA product code: PTA). This AncestryDNA Factor V Leiden Genetic Health Risk Test reports whether an individual has variants associated with a higher risk of developing harmful blood clots. This report is based on a qualitative genetic test for single nucleotide polymorphism detection of Factor V Leiden variant in the $F_5$ gene (rs6025).

Rationale/Source
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Description
Inherited thrombophilias are a group of disorders that predispose individuals to thrombosis. Genetic testing is available for some of these disorders and could assist in the diagnosis and/or management of patients with thrombosis. For example, testing is available for types of inherited thrombophilia, including variants in the 5,10-methylenetetrahydrofolate reductase ($MTHFR$) gene, the $factor\ V$ gene (factor V Leiden [$FVL$] variant), and the prothrombin ($factor\ II$) gene.

Summary of Evidence
For individuals who are asymptomatic with or without a personal or family history of venous thromboembolism (VTE) or who are asymptomatic with increased VTE risk (eg, due to pregnancy) who receive genetic testing for variants in $MTHFR$, or genetic testing for coagulation $factor\ V$ and coagulation $factor\ II$, the evidence includes a large randomized controlled trial, prospective cohort analyses, retrospective family studies, case-control studies, and meta-analyses. Relevant outcomes
Genetic Testing for Inherited Thrombophilia

Policy # 00333
Original Effective Date: 12/19/2012
Current Effective Date: 01/09/2023

are morbid events and treatment-related morbidity. The clinical validity of genetic testing has been demonstrated by the presence of an FVL variant or a prothrombin gene variant, and an association with an increased risk for subsequent VTE across various populations studied. However, the magnitude of the association is relatively modest, with odds ratios (OR) most commonly between 1 and 2, except for family members of individuals with inherited thrombophilia, for whom ORs are somewhat higher. The clinical utility of testing for FVL or prothrombin variants has not been demonstrated. Although the presence of inherited thrombophilia increases the risk for subsequent VTE events, the increase is modest, and the absolute risk of thrombosis remains low. Available prophylactic treatments (eg, anticoagulation) have defined risks of major bleeding and other adverse events that may outweigh the reduction in VTE and therefore result in net harm. Currently, available evidence has not defined a role for thrombophilia testing for decisions on initiation of prophylactic anticoagulation or the length of anticoagulation treatment. For MTHFR testing, clinical validity and clinical utility of genetic testing are uncertain. Because clinical utility of testing for elevated serum homocysteine itself has not been established, the utility of genetic testing also has not been established. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Supplemental Information
Clinical Input from Physician Specialty Societies and Academic Medical Centers
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2012 Input
In response to requests, input was received from 4 physician specialty societies (6 reviewers) and 6 academic medical centers, for a total of 12 reviewers, while this policy was under review in 2012. Input was mixed, and there was no consensus that genetic testing for thrombophilia was medically necessary for any of the specific clinical situations included. Several reviewers noted that testing could be useful in isolated instances but were unable to define specific criteria for testing.
Genetic Testing for Inherited Thrombophilia

Policy # 00333  
Original Effective Date: 12/19/2012  
Current Effective Date: 01/09/2023

Practice Guidelines and Position Statements
Guidelines or position statements will be considered for inclusion in ‘Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

Many guidelines and position statements on testing for thrombophilia have been published over the last 2 decades. These guidelines have evolved over time, are often inconsistent, and do not typically give specific parameters on when to perform genetic testing. The following are examples of U.S. guidelines developed by major specialty societies and published more recently.

American Board of Internal Medicine Foundation- Choosing Wisely Campaign
Choosing Wisely, an initiative of the American Board of Internal Medicine Foundation, seeks to promote discussions between clinicians and patients to choose care that is: supported by evidence, not duplicative of other tests or procedures already received, free from harm, and truly necessary. Medical specialty societies and their national organizations have identified tests or procedures commonly used in their field whose necessity should be questioned and discussed. The following medical specialist groups have contributed recommendations to Choosing Wisely lists specifically related to testing for inherited thrombophilias (Table 2).

Table 2. Medical Society Recommendations on Testing for Inherited Thrombophilias

<table>
<thead>
<tr>
<th>Society</th>
<th>Year</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Society of Hematology</td>
<td>2013</td>
<td>“Don’t test for thrombophilia in adult patients with venous thromboembolism (VTE) occurring in the setting of major transient risk factors (surgery, trauma or prolonged immobility).”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>“Thrombophilia testing is costly and can result in harm to patients if the duration of anticoagulation is inappropriately prolonged or if patients are incorrectly labeled as thrombophilic. Thrombophilia testing does not change the management of VTEs occurring in the</td>
</tr>
</tbody>
</table>
setting of major transient VTE risk factors. When VTE occurs in the setting of pregnancy or hormonal therapy, or when there is a strong family history plus a major transient risk factor, the role of thrombophilia testing is complex and patients and clinicians are advised to seek guidance from an expert in VTE.”

<table>
<thead>
<tr>
<th>Society for Maternal-Fetal Medicine</th>
<th>2014</th>
<th>“Don’t do an inherited thrombophilia evaluation for women with histories of pregnancy loss, intrauterine growth restriction (IUGR), preeclampsia and abruption.”</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>“Scientific data supporting a causal association between either methylenetetrahydrofolate reductase (MTHFR) polymorphisms or other common inherited thrombophilias and adverse pregnancy outcomes, such as recurrent pregnancy loss, severe preeclampsia and IUGR, are lacking. Specific testing for antiphospholipid antibodies, when clinically indicated, should be limited to lupus anti-coagulant, anticardiolipin antibodies and beta 2 glycoprotein antibodies.”</td>
</tr>
<tr>
<td>American Society for Reproductive Medicine</td>
<td>2013</td>
<td>“Don’t routinely order thrombophilia testing on patients undergoing a routine infertility evaluation.”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>“There is no indication to order these tests, and there is no benefit to be derived in obtaining them in someone that does not have any history of bleeding or abnormal clotting and in the absence of any family history. This testing is not a part of the infertility workup. Furthermore, the testing is costly, and there are risks associated with the proposed treatments, which would also not be indicated in this routine population.”</td>
</tr>
</tbody>
</table>
Genetic Testing for Inherited Thrombophilia

Policy # 00333
Original Effective Date: 12/19/2012
Current Effective Date: 01/09/2023

| American College of Medical Genetics and Genomics | 2015 | "Don't order MTHFR genetic testing for the risk assessment of hereditary thrombophilia." |
| American Society of Hematology and American Society of Pediatric Hematology/Oncology | 2019 | "Don't order thrombophilia testing on children with venous access (i.e., peripheral or central) associated thrombosis in the absence of a positive family history." |

American College of Chest Physicians
Since 2016, the American College of Chest Physicians (2021) guidelines and expert panel report on antithrombotic therapy for venous thromboembolism (VTE) disease no longer includes recommendations for pregnant women with known factor V Leiden or prothrombin G20210A variants, which had been included in the 2012 edition. Also, there are no guidelines on genetic testing for thrombophilia. The 2008 edition had indicated that the presence of a hereditary thrombophilia was not a major factor to guide duration of anticoagulation for VTE.

American College of Medical Genetics and Genomics
In 2018, the American College of Medical Genetics and Genomics (ACMG) published updated technical standards for genetic testing for variants associated with VTE, with a focus on factor V Leiden and factor II. The standards do not make recommendations on the indications for testing, and the authors note that testing indications from different professional organizations vary, referring to a review of professional society guidelines published by De Stefano et al (2013).

American College of Obstetricians and Gynecologists
The American College of Obstetricians and Gynecologists (2018) published management guidelines for inherited thrombophilias in pregnancy. These guidelines stated that a definitive causal link between inherited thrombophilias and adverse pregnancy outcomes could not be made. Screening for inherited thrombophilias is controversial, but may be considered for pregnant women in the following situations if testing will influence management:

- A personal history of VTE, with or without a recurrent risk factor, and no prior thrombophilia testing.
- A first-degree relative (eg, parent, sibling) with a history of high-risk thrombophilia.
Table 3. Guidelines for Managing Inherited Thrombophilias During Pregnancy

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>GOE</th>
<th>LOE</th>
</tr>
</thead>
<tbody>
<tr>
<td>In women with personal histories of VTE, testing for inherited thrombophilias should include FVL, prothrombin G20210A mutation, and tests for deficiencies in antithrombin, protein S and protein C</td>
<td>C</td>
<td>Consensus and expert opinion</td>
</tr>
<tr>
<td>Testing for inherited thrombophilias in women who have experienced fetal loss or adverse pregnancy outcomes, including placental abruption, preeclampsia, or fetal growth restriction, is not recommended because there is insufficient evidence that anticoagulation therapy reduces recurrence</td>
<td>B</td>
<td>Limited or inconsistent scientific evidence</td>
</tr>
<tr>
<td>Because an association between either heterozygosity or homozygosity for the MTHFR C677T polymorphism and any negative pregnancy outcomes, including any increased risk for VTE, has not been shown, screening with either MTHFR mutation analyses or fasting homocysteine levels is not recommended</td>
<td>B</td>
<td>Limited or inconsistent scientific evidence</td>
</tr>
</tbody>
</table>

FVL: factor V Leiden; GOE: grade of evidence; LOE: level of evidence; VTE: venous thromboembolism.

Anticoagulation Forum

In 2016, Stevens et al. published a guidance document initiated by the Anticoagulation Forum. The guidance was intended to inform clinical decisions regarding duration of anticoagulation following VTE and primary prevention of VTE in relatives of affected patients. Statements were based on existing guidelines and consensus expert opinion when guidelines were lacking. The authors concluded that, "Thrombophilia testing is performed far more frequently than can be justified based on available evidence; the majority of such testing is not of benefit to the patient and may be harmful." Table 4 summarizes the guidance statements for each question considered in the document.
Table 4. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia (adapted from Stevens et al [2016])

<table>
<thead>
<tr>
<th>Question</th>
<th>Guidance Statement</th>
<th>Limits/Exceptions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Should thrombophilia testing be performed to help determine duration of anticoagulation following provoked VTE?</td>
<td>Do not perform thrombophilia testing following an episode of provoked VTE.</td>
<td></td>
</tr>
<tr>
<td>Should thrombophilia testing be performed to help determine duration of anticoagulation following unprovoked VTE?</td>
<td>Do not perform thrombophilia testing in patients following an episode of unprovoked VTE.</td>
<td>If a patient with unprovoked VTE and low bleeding risk is planning to stop anticoagulation, test for thrombophilia if test results would change this decision.</td>
</tr>
<tr>
<td>Should family members of patients with VTE or hereditary thrombophilia undergo thrombophilia testing?</td>
<td>Do not test for thrombophilia in asymptomatic family members of patients with VTE or hereditary thrombophilia.</td>
<td></td>
</tr>
<tr>
<td>Should female relatives of patients with VTE or hereditary thrombophilia who are considering using estrogen-containing medications be tested for thrombophilia?</td>
<td>Do not test for thrombophilia in asymptomatic family members of patients with VTE or hereditary thrombophilia who are contemplating use of estrogen.</td>
<td>If a woman contemplating estrogen use has a first degree relative with VTE and a known hereditary thrombophilia, test for that thrombophilia if the result would change the decision to use estrogen.</td>
</tr>
<tr>
<td>Should female relatives of patients with VTE or hereditary thrombophilia who are contemplating pregnancy be tested for thrombophilia?</td>
<td>Do not test for thrombophilia in asymptomatic family members of patients with VTE or hereditary thrombophilia who are contemplating pregnancy.</td>
<td>If a woman contemplating pregnancy has a first degree relative with VTE and a...</td>
</tr>
</tbody>
</table>
Genetic Testing for Inherited Thrombophilia

Policy # 00333
Original Effective Date: 12/19/2012
Current Effective Date: 01/09/2023

<table>
<thead>
<tr>
<th>hereditary thrombophilia who are contemplating pregnancy be tested for thrombophilia?</th>
<th>asymptomatic family members of patients with VTE or hereditary thrombophilia who are contemplating pregnancy.</th>
<th>known hereditary thrombophilia, test for that thrombophilia if the result would change VTE prophylaxis decisions.</th>
</tr>
</thead>
</table>

When thrombophilia testing is performed, at what point in the patient’s care should this be done?

Do not perform thrombophilia testing at the time of VTE diagnosis or during the initial 3-month course of anticoagulant therapy. When testing for thrombophilias following VTE, use either a 2-stage testing approach or perform testing after a minimum of 3 months of anticoagulant therapy has been completed, and anticoagulants have been held.

VTE: Venous thromboembolism.

Evaluation of Genomic Applications in Practice and Prevention
The Evaluation of Genomic Applications in Practice and Prevention (2011) recommendations did not support the clinical utility of genetic testing for factor V Leiden and prothrombin variants for prevention of initial episodes of VTE or for recurrence. The recommendations have been archived.

U.S. Preventive Services Task Force Recommendations
Not applicable.
Genetic Testing for Inherited Thrombophilia

Policy #  00333  
Original Effective Date:  12/19/2012  
Current Effective Date:  01/09/2023

Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
Some currently unpublished trials that might influence this review are listed in Table 5.

Table 5. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unpublished</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02841085</td>
<td>Search for New Mutations Genetic Predisposing to an Increased Risk Venous Thromboembolic Disease Idiopathic. Study &quot;FIT GENETIQUE&quot;</td>
<td>613</td>
<td>May 2021</td>
</tr>
<tr>
<td>NCT02685800</td>
<td>A Registry on Outcomes in Women Undergoing Assisted Reproductive Techniques After Recurrent Failures</td>
<td>624</td>
<td>Sep 2020</td>
</tr>
<tr>
<td>NCT02385461</td>
<td>Study on Antithrombotic Prevention in Thrombophilia and Pregnancy Loss (OTTILIA)</td>
<td>108</td>
<td>Dec 2020</td>
</tr>
<tr>
<td>NCT02407730</td>
<td>Effects of Thrombophilia on the Outcomes of Assisted Reproduction Technologies</td>
<td>687</td>
<td>May 2018</td>
</tr>
<tr>
<td>NCT02986594</td>
<td>Diagnosis and Treatment Strategy of Recurrent Spontaneous Abortion Associated With Thrombophilia</td>
<td>600</td>
<td>Oct 2019</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

References
Genetic Testing for Inherited Thrombophilia

Policy # 00333
Original Effective Date: 12/19/2012
Current Effective Date: 01/09/2023


©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Genetic Testing for Inherited Thrombophilia

Policy # 00333
Original Effective Date: 12/19/2012
Current Effective Date: 01/09/2023

Genetic Testing for Inherited Thrombophilia

Policy # 00333
Original Effective Date: 12/19/2012
Current Effective Date: 01/09/2023


©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Genetic Testing for Inherited Thrombophilia

Policy # 00333
Original Effective Date: 12/19/2012
Current Effective Date: 01/09/2023


Policy History

Original Effective Date: 12/19/2012
Current Effective Date: 01/09/2023

12/06/2012 Medical Policy Committee review
12/19/2012 Medical Policy Implementation Committee approval. New policy.
11/07/2013 Medical Policy Committee review
Genetic Testing for Inherited Thrombophilia

Policy # 00333
Original Effective Date: 12/19/2012
Current Effective Date: 01/09/2023

12/04/2014 Medical Policy Committee review
08/03/2015 Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
12/03/2015 Medical Policy Committee review
12/16/2015 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
12/01/2016 Medical Policy Committee review
01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
12/07/2017 Medical Policy Committee review
12/20/2017 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
12/06/2018 Medical Policy Committee review
12/19/2018 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
12/05/2019 Medical Policy Committee review
12/11/2019 Medical Policy Implementation Committee approval. The policy is revised with updated genetics nomenclature; “mutations” changed to “variants” throughout policy. Coverage eligibility unchanged.
12/03/2020 Medical Policy Committee review
12/02/2021 Medical Policy Committee review
12/01/2022 Medical Policy Committee review
12/14/2022 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 12/2023

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Page 20 of 22
Genetic Testing for Inherited Thrombophilia

Policy # 00333
Original Effective Date: 12/19/2012
Current Effective Date: 01/09/2023

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2021 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>81240, 81241, 81291, 81400</td>
</tr>
<tr>
<td>HCPCS</td>
<td>No codes</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>All related diagnoses</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into
Genetic Testing for Inherited Thrombophilia

Policy #  00333
Original Effective Date:  12/19/2012
Current Effective Date:  01/09/2023

standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.